P. Schmid

Statistics

Publications

Citations

H-Index

Active since

2024

Affiliations

Queen Mary University of London(Current)

Fudan University Shanghai Cancer Center

Princess Margaret Cancer Centre

P. Schmid is an author at Queen Mary University of London specializing in neoadjuvant hormonal therapy, her2-positive breast cancer therapy, and neoadjuvant therapy.

Publications per year

2024–2025

Publications

LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial

R. Dent, Zhi-Ming Shao, P. Schmid et al. · Annals of Oncology · 2025 · 21 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: Results from the phase 3 KEYNOTE-756 study

Fátima Cardoso, J. O’Shaughnessy, Heather L. McArthur et al. · European Journal of Cancer · 2024 · 11 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

1–2 of 2